Thursday, June 08, 2023 2:44:02 PM
ATLnsider,
Yes and Direct being a tumor microenvironment modulator will not require all the other “stuff” IF administered correctly because the immune response will be monitored properly for a sufficient time period to achieve immune memory in T-cells, B-cells and DCs. In some very aggressive cancer situations this holds true for L too even without immune surveillance provided by L. In some cases it can recruit immune surveillance from existing immune cells called to the site where sufficient inflammatory response occurs, ie Kat’s cure and Mr. Powers radical turn around from certain death to life.
This threat is why so many try so hard to under value this platform so that it can be bought cheaply from those not understanding what is truly at stake. Linda Powers is setting this up by preparing ahead of time so that this attempt can only gain limited success. Best wishes.
Yes and Direct being a tumor microenvironment modulator will not require all the other “stuff” IF administered correctly because the immune response will be monitored properly for a sufficient time period to achieve immune memory in T-cells, B-cells and DCs. In some very aggressive cancer situations this holds true for L too even without immune surveillance provided by L. In some cases it can recruit immune surveillance from existing immune cells called to the site where sufficient inflammatory response occurs, ie Kat’s cure and Mr. Powers radical turn around from certain death to life.
This threat is why so many try so hard to under value this platform so that it can be bought cheaply from those not understanding what is truly at stake. Linda Powers is setting this up by preparing ahead of time so that this attempt can only gain limited success. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
